Oncology Research Information Exchange Network (ORIEN)

The Oncology Research Information Exchange Network (ORIEN) brings together North America’s top cancer centers in a unique research partnership. This partnership aims to improve the standard of cancer care by helping to develop new:

  • Cancer research
  • Clinical trials
  • Technology
  • Informatics solutions
  • Personalized medicine


ORIEN was founded in 2014 by the Moffitt Cancer Center in Tampa, Florida, and the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio. The UVA Cancer Center joined ORIEN in February 2015. As of November 2019, ORIEN contains 19 member sites.

Learn more about the national ORIEN program.

Total Cancer Care: Data & Tissue Repository

To bring new translational research to the community, the ORIEN consortium developed Total Cancer Care (TCC), a centralized clinical data and tissue repository. At UVA, the protocol is entitled Partners in Discovery for Total Cancer Care at UVA and referred to as the ORIEN protocol.

TCC collects blood and tissue samples, including their associated demographic and clinical data (survey data, medical records data, cancer registry data, and other related data), from thousands of patients with cancer or at risk of having cancer.

Additionally, the ORIEN AVATAR program collects paired tumor and non-tumor tissue for whole exome sequencing and RNAseq.

Learn more about patient participation.

ORIEN Team and Partnerships

The ORIEN Team at the UVA Cancer Center has developed partnerships with many groups for an efficient workflow, including:

  • ORIEN core team
  • Clinical labs
  • Clinical teams
  • BTRF
  • Surgical pathology
  • Research and clinical trial analytics

ORIEN Core Functions

The ORIEN clinical research coordinators work closely with the clinical teams and approach patients to discuss the ORIEN protocol. Upon consent, the team coordinates a variety of sample collections that may include blood products in addition to remnant surgical tissue and buccal swabs. 

Genetic Sequencing via ORIEN AVATAR

For patients with adequate tumor and germline sample sets:

  • Tumor DNA 300X
  • Tumor RNA 100 million reads
  • Germline DNA 100X

Resources for Investigators

Through the biobanking efforts of the ORIEN team and the BTRF, our investigators will have access to a variety of resources:

  • Clinical Data Services
  • Molecular Data Access with Clinical Data
  • Specimen Management
  • Study Management of Non-Treatment Studies

Clinical Data Services

  • Data abstractions from EPIC to complete Case Report Forms
  • Coordinate upload of EPIC data extractions into REDCap or other data capture systems
  • Queries on internal and external ORIEN databases for project feasibility
  • Coordinate with Research and Clinical Trial Analytics Team and Cancer Registry for project data needs
    • Feasibility for grant applications
    • Feasibility for clinical trials for actual number of qualifying patients

Molecular Data Access with Clinical Data

  • Queries using ORIEN Qlik and ORIEN CBioPortal
  • Project-specific access to molecular files downloaded to Rivanna for UVA consented patients – does not include analysis
  • Project submissions for ORIEN inter-member projects to gain access to molecular data from patients consented at other ORIEN sites
    • Use of ORIEN CBioPortal data in grants and publications
    • Access to raw files for own analysis

Specimen Management

Studies may either rely on the specimen management that is part of the ORIEN protocol through the ORIEN core functions or may rely on an independent protocol with consent with unique specimen criteria. For those studies that rely on the ORIEN protocol, the following table provides the collection details.


Tube Type

Collection Volume

Collection Limit



Blood from solid tumor patient


10 mL

cumulative blood collection total of 60 mL/8wk

1 mL whole blood stored for future germline sequencing, remainder stored as buffy coat and 1 mL plasma aliquots

Modification to usual collection or processing generate additional charges

Blood from blood cancer patient

Na heparin

20 mL

cumulative blood collection total of 60 mL/8wk

viably frozen mononuclear cell aliquots

Modification to usual collection or processing generate additional charges

Blood from blood cancer patient: For Circulating tumor DNA

Streck tube

10 mL

cumulative blood collection total of 60 mL/8wk determined on project specific basis

project specific basis and fees apply

Bone marrow aspirates

Sodium heparin

10 mL

10 mL/4wk

viably frozen mononuclear cell aliquots


Buccal swabs


1 swab kit

2 per year

cell suspension


Lymph Node FNA

extra pass (blood cancers only)


2 extra passes

snap frozen for cores, RPMI for FNA


Study Management

  • Pre-screening of potential study participants
  • Compliant consent of study participants
  • Survey administration and phone follow-up
  • Specimen coordination, processing and shipping
  • Chart review / case report form completion

How to Access Resources

When completing the IRB determination of human subjects form, please use the following templated language as part of the project description: BACKGROUND: Under IRB-HSR 18445: UVA allows M2Gen, coordinating center for ORIEN, to provide researchers access to the coded linked whole exome sequencing and RNA sequencing files and the associated coded linked clinical data via a statement of work under the ORIEN Master Tissue and Data Use Agreement. The data and specimens for 18445 are linked and coded. The key to the code is maintained by the ORIEN study team. Study teams receiving data from this repository cannot re-identify the data (or specimens) they receive to perform their research because policies are in place to protect the privacy of subjects enrolled in 18445 and disallow the sharing of keys to the code. There is no collaboration between the researchers and the supplier of the samples/data.